Twinbeech Capital LP Sells 35,683 Shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX)

Twinbeech Capital LP reduced its position in shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX - Free Report) by 54.5% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 29,776 shares of the company's stock after selling 35,683 shares during the quarter. Twinbeech Capital LP's holdings in Nurix Therapeutics were worth $561,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. US Bancorp DE raised its holdings in Nurix Therapeutics by 144.7% during the 4th quarter. US Bancorp DE now owns 1,424 shares of the company's stock valued at $27,000 after buying an additional 842 shares during the last quarter. Aquatic Capital Management LLC purchased a new position in Nurix Therapeutics during the 4th quarter valued at $87,000. Summit Investment Advisors Inc. increased its position in Nurix Therapeutics by 13.6% during the 4th quarter. Summit Investment Advisors Inc. now owns 7,345 shares of the company's stock valued at $138,000 after purchasing an additional 877 shares during the period. BNP Paribas Financial Markets purchased a new position in Nurix Therapeutics during the 4th quarter valued at $164,000. Finally, Nomura Holdings Inc. purchased a new position in Nurix Therapeutics during the 4th quarter valued at $198,000.

Insider Activity at Nurix Therapeutics

In related news, insider Gwenn Hansen sold 3,377 shares of the stock in a transaction dated Wednesday, April 30th. The shares were sold at an average price of $11.50, for a total transaction of $38,835.50. Following the sale, the insider now directly owns 61,516 shares of the company's stock, valued at approximately $707,434. This represents a 5.20% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CFO Houte Hans Van sold 2,438 shares of the stock in a transaction dated Wednesday, April 30th. The shares were sold at an average price of $11.50, for a total transaction of $28,037.00. Following the sale, the chief financial officer now directly owns 39,922 shares in the company, valued at $459,103. This trade represents a 5.76% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 17,838 shares of company stock valued at $221,500. 7.40% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

A number of brokerages have issued reports on NRIX. JPMorgan Chase & Co. reduced their price objective on shares of Nurix Therapeutics from $31.00 to $30.00 and set an "overweight" rating on the stock in a research report on Wednesday, January 29th. Needham & Company LLC reissued a "buy" rating and set a $27.00 price objective on shares of Nurix Therapeutics in a research report on Tuesday, April 29th. Leerink Partnrs raised shares of Nurix Therapeutics to a "hold" rating in a research report on Monday, March 17th. Stifel Nicolaus reduced their price objective on shares of Nurix Therapeutics from $36.00 to $35.00 and set a "buy" rating on the stock in a research report on Wednesday, April 9th. Finally, HC Wainwright reissued a "buy" rating and set a $36.00 price objective on shares of Nurix Therapeutics in a research report on Wednesday, April 2nd. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and sixteen have issued a buy rating to the company's stock. According to data from MarketBeat, Nurix Therapeutics presently has a consensus rating of "Moderate Buy" and an average target price of $30.44.

Nurix Therapeutics Price Performance

NASDAQ:NRIX opened at $9.99 on Friday. The firm's 50-day moving average price is $10.75 and its 200-day moving average price is $16.50. The company has a market capitalization of $761.60 million, a PE ratio of -3.46 and a beta of 2.23. Nurix Therapeutics, Inc. has a 1-year low of $8.18 and a 1-year high of $29.56.

Nurix Therapeutics (NASDAQ:NRIX - Get Free Report) last announced its quarterly earnings data on Tuesday, April 8th. The company reported ($0.67) EPS for the quarter, beating the consensus estimate of ($0.72) by $0.05. Nurix Therapeutics had a negative net margin of 354.85% and a negative return on equity of 53.65%. The company had revenue of $18.45 million for the quarter, compared to the consensus estimate of $12.78 million. During the same period in the prior year, the firm posted ($0.76) EPS. Equities analysts anticipate that Nurix Therapeutics, Inc. will post -2.99 EPS for the current fiscal year.

About Nurix Therapeutics

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.

Want to see what other hedge funds are holding NRIX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Nurix Therapeutics, Inc. (NASDAQ:NRIX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.